宫颈癌是由高危型人乳头瘤病毒(HR-HPV)感染引起的。它是埃塞俄比亚和全球癌症相关死亡的主要原因之一。为了开发有效的疫苗接种和基于HPV的宫颈癌筛查方法,关于HPV基因型分布的数据至关重要。因此,本研究旨在回顾埃塞俄比亚的HPV基因型分布.
使用来自PubMed/Medline和SCOPUS的综合搜索字符串系统地搜索研究文章。此外,谷歌学者被手动搜索灰色文献。最后一次搜索是在2021年8月18日进行的。前两位作者独立评估了研究的科学质量,并使用Excel表格提取了数据。汇集的HPV基因型分布以描述性统计呈现。
我们纳入了2005年和2019年来自全国不同地区的10项研究。这些研究包括3633名患有不同类型宫颈异常的女性,报告了29种不同的HPV基因型和1926种序列。高风险的比例,可能/可能的高风险和低风险HPV为1493(77.5%),182(9.4%)和195(10.1%),分别。在报告的基因型中,前五名是HPV16(37.3%;95%CI35.2.1-39.5%),HPV52(6.8%;95%CI5.8-8.0%),HPV35(4.8%;95%CI3.9-5.8%),HPV18(4.4%;95%CI3.5-5.3%)和HPV56(3.9%:95%CI3.1-4.9%)。其他一些HR-HPV组包括HPV31(3.8%),HPV45(3.5%),HPV58(3.1%),HPV59(2.3%),和HPV68(2.3%)。在高风险类型中,HPV16/18的合并患病率为53.7%(95%CI51.2~56.3%).HPV11(2.7%:95%CI2.1-3.5%),HPV42(2.1%:95%CI1.5-2.8%)和HPV6(2.1%:95%CI1.4-2.7%)是最常见的低风险HPV类型。
我们注意到HR-HPV类型的比例更高,特别是HPV16,而且HPV52,HPV35和HPV18,在埃塞俄比亚的疫苗接种和基于HPV的宫颈筛查计划中需要特别注意。需要来自该国其他地区的其他数据,这些地区以前没有HPV基因型报告,以更好地绘制埃塞俄比亚的国家HPV基因型分布图。
Cervical cancer is caused by infection with high-risk human papillomaviruses (HR-HPVs). It is one of the leading causes of cancer-related deaths in Ethiopia and globally. To develop efficient vaccination and HPV-based cervical cancer screening approaches, data on genotype distribution of HPVs is crucial. Hence, the study was aimed to
review HPV genotype distribution in Ethiopia.
Research articles were systematically searched using comprehensive search strings from PubMed/Medline and SCOPUS. Besides, Google Scholar was searched manually for grey literature. The last search was conducted on 18 August 2021. The first two authors independently appraised the studies for scientific quality and extracted the data using Excel sheet. The pooled HPV genotype distribution was presented with descriptive statistics.
We have included ten studies that were reported from different parts of the country during 2005 and 2019. These studies included 3633 women presented with different kinds of cervical abnormalities, from whom 29 different HPV genotypes with a sum of 1926 sequences were reported. The proportion of high-risk, possible/probable high-risk and low-risk HPVs were at 1493 (77.5%), 182 (9.4%) and 195 (10.1%), respectively. Of the reported genotypes, the top five were HPV 16 (37.3%; 95% CI 35.2.1-39.5%), HPV 52 (6.8%; 95% CI 5.8-8.0%), HPV 35 (4.8%; 95% CI 3.9-5.8%), HPV 18 (4.4%; 95% CI 3.5-5.3%) and HPV 56 (3.9%: 95% CI 3.1-4.9%). Some of other HR-HPV groups include HPV 31 (3.8%), HPV 45 (3.5%), HPV 58 (3.1%), HPV 59(2.3%), and HPV 68 (2.3%). Among the high-risk types, the combined prevalence of HPV 16/18 was at 53.7% (95% CI 51.2-56.3%). HPV 11 (2.7%: 95% CI 2.1-3.5%), HPV 42 (2.1%: 95% CI 1.5-2.8%) and HPV 6 (2.1%: 95% CI 1.4-2.7%) were the most common low-risk HPV types.
We noted that the proportion of HR-HPV types was higher and HPV 16 in particular, but also HPV 52, HPV 35 and HPV 18, warrant special attention in Ethiopian\'s vaccination and HPV based cervical screening program. Additional data from other parts of the country where there is no previous HPV genotype report are needed to better map the national HPV genotypes distribution of Ethiopia.